REVIEW Manidipine dihydrochloride is a racemic, lipophilic, third-generation dihydropyridine calcium channel blocker used as an antihypertensive. It has high selectivity for the vasculature, inducing marked peripheral vasodilation with negligible cardiodepression. In addition, manidipine does not significantly affect norepinephrine levels, suggesting a lack of sympathetic activation.
Meguro, Kanji; Nagaoka, Akinobu Dihydropyridine derivatives and their use Eur. Pat. Appl. (1983), EP 94159 A1 19831116.
Meguro, Kanji; Aizawa, Masahiro; Sohda, Takashi; Kawamatsu, Yutaka; Nagaoka, Akinobu New 1,4-dihydropyridine derivatives with potent and long-lasting hypotensive effect Chemical & Pharmaceutical Bulletin (1985), 33(9), 3787-97.
Kakihana, Mitsuru; Suno, Masahiro; Nagaoka, Akinobu Antihypertensive effect of CV-4093, a new calcium antagonist, in three rat models of hypertension Japanese Journal of Pharmacology (1988), 48(2), 223-8.
Ruggenenti P, Lauria G, Iliev IP, Fassi A, Ilieva AP, Rota S, Chiurchiu C, Barlovic DP, Sghirlanzoni A, Lombardi R, Penza P, Cavaletti G, Piatti ML, Frigeni B, Filipponi M, Rubis N, Noris G, Motterlini N, Ene-Iordache B, Gaspari F, Perna A, Zaletel J, Bossi A, Dodesini AR, Trevisan R, Remuzzi G; DEMAND Study Investigators (2011). Effects of manidipine and delapril in hypertensive patients with type 2 diabetes mellitus: the delapril and manidipine for nephroprotection in diabetes (DEMAND) randomized clinical trial. Hypertension. 58(5):776-83. PMID 21931073.